Equfina Adverse Reactions

Summary of the safety profile: Dyskinesia was the most common adverse reaction reported in safinamide patients when used in combination with L-dopa alone or in combination with other PD treatments.
Serious adverse reactions are known to occur with the concomitant use of SSRIs, SNRIs,
tricyclic/tetracyclic antidepressants and MAO inhibitors, such as hypertensive crisis (high blood pressure, collapse), neuroleptic malignant syndrome (confusion, sweating, muscle rigidity, hyperthermia, CPK increase), serotonin syndrome (confusion, hypertension, muscle stiffness, hallucinations), and hypotension. With MAO-inhibitors there have been reports of drug interactions with concomitant use of sympathomimetic medicinal products.
Impulse control disorders; pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments.
Tabulated list of adverse reactions: The tabulation as follows includes all adverse reactions in clinical trials where adverse reactions were considered related.
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data). (See Table 2.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Dyskinesia occurred early in treatment, was rated "severe", led to discontinuation in very few patients (approx. 1.5%), and did not require reduction of dose in any patient.